

A Novel Anti-CD43 Monoclonal Antibody

Drug Name	***0068
Description	A monoclonal antibody targeting an epitope of the extracellular domain of
	leukosialin (CD43) is in early clinical investigation for the treatment of leukemia.
Target	CD34
Drug Modality	Antibody
Indication	Leukemia
Product Category	Cancer Immunotherapy
Mechanism of Action	Anti-CD43
Status	Phase I
Patent	Granted

More Detail Available Upon Request

We look forward to hearing from you.

E-mail: inquiry@protheragen.com www.protheragen.com 101-4 Colin Dr, Holbrook, NY 11741, USA